SAM LNP S TCE
Alternative Names: GRT R910; GRT-R912; GRT-R914; SAM-LNP-S-TCELatest Information Update: 07 May 2024
At a glance
- Originator Gritstone bio
- Developer Gritstone bio; National Institute of Allergy and Infectious Diseases
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 07 May 2024 Phase-I development in COVID-2019-infections (In the elderly, Prevention, In adults) is ongoing in USA
- 30 Apr 2024 Immunogenicity and adverse events data from a phase I CORAL-CEPI trial in COVID-2019 infections released by Gritstone bio
- 28 Apr 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(In the elderly, Prevention, In adults) in USA